Prevnar 20

Sickle Cell Disease

SanofivaccinePhase 3Active

CCC

52/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 45/ 100
Competitive Position: 65/ 100

Competitive context

132 Active assets in the Sickle Cell Disease cohort.

Asset / Sponsor	Phase	Rating
Glutamine Ain Shams University	Phase 4	BBB
Hydroxyurea St. Jude Children's Research Hospital	Phase 4	BB
Nivestim St. Jude Children's Research Hospital	Phase 4	BB
Magnesium Metallicum Medical College of Wisconsin	Phase 3	BB
Crizanlizumab Novartis Pharmaceuticals	Phase 4	BB

View all 50 →

Same molecule, other indications

Prevnar 20 is also rated in:

pneumococcal infectionActive

BB

Indicative · Phase 4

65 / 100

non-Hodgkin lymphomaActive

B

Indicative · Phase 4

59 / 100

lymphomaActive

B

Indicative · Phase 4

56 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.